skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Update on the use of pramipexole in the treatment of Parkinson’s disease

Review

(2471) Views  (573) Full article downloads

Authors: Radu Constantinescu

Published Date April 2008 Volume 2008:4(2) Pages 337 - 352
DOI: http://dx.doi.org/10.2147/NDT.S2325

Radu Constantinescu

Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden

Abstract: Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson’s disease (PD). This review addresses the literature concerning pramipexole’s efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances.

Keywords: pramipexole, Parkinson’s disease, efficacy, adverse events








Readers of this article also read:

The prognostic value of injury severity, location of event, and age at injury in pediatric traumatic head injuries
Current approaches to the treatment of Parkinson’s disease
Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Editorial
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease